IOL

Different corneal diseases present different challenges to achieving the desired refractive outcome after cataract surgery. Cornea specialist Dasa V. Gangadhar, MD, highlights measures to consider in various situations.

The unique properties of a light-adjustable lens are designed to provide predictable results and customized refractive treatments.

Despite the advent of advanced technologies-such as corneal stromal collagen crosslinking (CXL), intracorneal ring segments (ICRS), toric phakic and pseudophakic IOLs, and keratoplasty-patients with keratoconus are mostly being managed with spectacles and/or contact lenses.

Implant exchange in multifocal IOL recipients unhappy with their vision is better performed sooner rather than later. It is even better to avoid the exchange whenever possible by identifying and addressing a treatable cause for the patient’s complaints.The best strategy of all is to prevent dissatisfaction in the first place by attention to patient selection and preoperative management, said Stephen G. Slade, MD.

In his debut blog, Dr. Packer writes of a cautionary tale to physicians when stuck between the wants and needs of married patients.

Highly variable myopia shifts can occur in pseudophakic children. IOL exchange seems to be an acceptable option for treating the high myopia that can develop with lens implantation in children.However, the use of IOLs in growing eyes remains controversial, and outcomes are uncertain because of lack of data, according to Courtney Kraus, MD.

A foldable, hydrophobic acrylic IOL embedded with a small-aperture mask provided excellent visual acuity across all distances in patients who underwent monocular implantation after cataract surgery and was not associated with any visual symptoms that may occur with other presbyopia-correcting IOLs.

With a wide array of IOL options available to their foreign colleagues, U.S. ophthalmologists eagerly await the approval and availability of additional lenses.

A new intraocular mini-telescope is easy to implant through a small incision and has optimized optics so that it reliably provides good quality vision.

Alcon recently announced a partnership to in-license Google’s smart lens technology, but many questions remain. What will this new product bring to eye care and will it change ocular medicine?

Rayner Intraocular Lenses Ltd. have launched a new injector, RaySert Plus, in the United States market after receiving 510(k) clearance from the FDA.

The recent agreement between Valeant and Croma-which would provide for the distribution of Croma’s ophthalmology products in Western Europe-is expected to expand Bausch + Lomb’s (B + L) ophthalmic portfolio in the United States.

The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.

The Synchrony dual-optic accommodative intraocular lens (Abbott Medical Optics) seems to be clinically safe and effective after 2 years of follow-up. The visual function at intermediate and far improved rapidly postoperatively. Half of patients require a +1 D prescription for near vision.

When consulting with patients who present with decreased vision due to cataracts, ophthalmologists need to remember their role as physicians first, suggest the authors. The primary goal of the office visit is to address the complaint and the solution in entirety before moving into outcomes.

Among the 2013 ASCRS clinical survey results on astigmatism, findings showed that 57% of physicians saw benefits associated with femtosecond laser arcuate incisions compared with conventional manual incisions. Other trends were identified from the more than 1,000 physician responses.

Early treatment of pediatric cataracts is crucial, with proper consideration being given to age and the type of postoperative correction to be used.

A dual-optic accommodating IOL (Synchrony, Abbott Medical Optics) seems to have met the presbyopic challenge by providing good vision at far and intermediate distances.

An array of IOLs under development and in clinical trials show promise for correcting presbyopia or addressing other limitations of existing pseudophakic lenses.

Bausch + Lomb have announced the U.S. introduction of BLIS (Bausch + Lomb Injector System), designed exclusively for use with the enVista glistening-free, hydrophobic acrylic IOL.

Numerous reports show that phacoemulsification lowers IOP, but further research is needed to understand what mediates the change, according to Douglas J. Rhee, MD.

A patient satisfaction and quality-of-life survey found that three presbyopia-correcting IOLs provide better spectacle independence than monovision.

The majority of cataract patients likely have significant tear film disturbances that can affect their preoperative measurements and postoperative satisfaction with cataract surgery.

Kevin Lavery, MD, describes his technique for implanting a 1-piece acrylic astigmatic lens (Tecnis Toric IOL, Abbott Medical Optics) through a 2.2-mm incision or even smaller.

Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.

A light-adjustable IOL continues to show potential for delivering customized vision with predictable results.

A single-piece hydrophobic acrylic IOL has many features that make it a good choice for a monofocal implant in routine and challenging cataract surgery cases.

Secondary IOL implantation is widely accepted, especially in aphakic patients who have become contact lens intolerant or noncompliant. A number of studies on the topic, mostly from Western countries, have had small sample sizes, and the safety and efficacy of the procedure have not been well studied.

The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of cataract patients with pre-existing corneal astigmatism.

It is not always easy to fit the right IOL to the right patient to correct presbyopia. It is not that approved lenses do not work as expected, according to Richard Chu, DO, medical director, Chu Eye Associates, Fort Worth, TX, but that each lens has slightly different optical characteristics. Not every lens is right for every patient.